Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 15/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 10/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083716 | 0.87 | L3MBTL3 (0.58) | CACNA1BNR1I2L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL1083745 | 0.85 | NR1I2 (0.52) | CACNA1BNR1I2L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL1083743 | 0.84 | LMNA (0.51) | CACNA1BNR1I2L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL1083720 | 0.80 | L3MBTL3 (0.53) | CACNA1BL3MBTL3L3MBTL1TP53BP1MBTD1 | |
| SCHEMBL1083719 | 0.80 | CCR5 (0.51) | L3MBTL3L3MBTL1TP53BP1MBTD1 | |
| SCHEMBL4418300 | 0.79 | CHRM2 (0.46) | CACNA1BNR1I2L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL1083699 | 0.79 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1TP53BP1MBTD1 | |
| SCHEMBL1085504 | 0.77 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1TP53BP1MBTD1 | |
| SCHEMBL1083710 | 0.77 | CCR5 (0.48) | L3MBTL3L3MBTL1TP53BP1MBTD1 | |
| SCHEMBL3035595 | 0.76 | CACNA1B (0.66) | CACNA1BNR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2205583-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009043747-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043747-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | CCR3, CCRL2, CCR2 | CACNA1B 3123/4885NR1I2 52/4885CYP3A4 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.